Cargando…

Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets

Background. MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders. Result. The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Qing, Li, Qiuxia, Zhang, Peizhuo, Jiang, Yingjuan, Wang, Xinwei, Wei, Qiujing, Cao, Shuangyan, Liao, Zetao, Lin, Zhiming, Pan, Yunfeng, Huang, Jianlin, Li, Tianwang, Jin, Ou, Wu, Yuqiong, Gu, Jieruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529895/
https://www.ncbi.nlm.nih.gov/pubmed/26273623
http://dx.doi.org/10.1155/2015/504208
_version_ 1782384835294134272
author Lv, Qing
Li, Qiuxia
Zhang, Peizhuo
Jiang, Yingjuan
Wang, Xinwei
Wei, Qiujing
Cao, Shuangyan
Liao, Zetao
Lin, Zhiming
Pan, Yunfeng
Huang, Jianlin
Li, Tianwang
Jin, Ou
Wu, Yuqiong
Gu, Jieruo
author_facet Lv, Qing
Li, Qiuxia
Zhang, Peizhuo
Jiang, Yingjuan
Wang, Xinwei
Wei, Qiujing
Cao, Shuangyan
Liao, Zetao
Lin, Zhiming
Pan, Yunfeng
Huang, Jianlin
Li, Tianwang
Jin, Ou
Wu, Yuqiong
Gu, Jieruo
author_sort Lv, Qing
collection PubMed
description Background. MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders. Result. The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR. Conclusion. AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS.
format Online
Article
Text
id pubmed-4529895
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-45298952015-08-13 Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets Lv, Qing Li, Qiuxia Zhang, Peizhuo Jiang, Yingjuan Wang, Xinwei Wei, Qiujing Cao, Shuangyan Liao, Zetao Lin, Zhiming Pan, Yunfeng Huang, Jianlin Li, Tianwang Jin, Ou Wu, Yuqiong Gu, Jieruo Biomed Res Int Clinical Study Background. MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders. Result. The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR. Conclusion. AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS. Hindawi Publishing Corporation 2015 2015-07-26 /pmc/articles/PMC4529895/ /pubmed/26273623 http://dx.doi.org/10.1155/2015/504208 Text en Copyright © 2015 Qing Lv et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Lv, Qing
Li, Qiuxia
Zhang, Peizhuo
Jiang, Yingjuan
Wang, Xinwei
Wei, Qiujing
Cao, Shuangyan
Liao, Zetao
Lin, Zhiming
Pan, Yunfeng
Huang, Jianlin
Li, Tianwang
Jin, Ou
Wu, Yuqiong
Gu, Jieruo
Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets
title Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets
title_full Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets
title_fullStr Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets
title_full_unstemmed Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets
title_short Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets
title_sort disorders of micrornas in peripheral blood mononuclear cells: as novel biomarkers of ankylosing spondylitis and provocative therapeutic targets
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529895/
https://www.ncbi.nlm.nih.gov/pubmed/26273623
http://dx.doi.org/10.1155/2015/504208
work_keys_str_mv AT lvqing disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT liqiuxia disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT zhangpeizhuo disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT jiangyingjuan disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT wangxinwei disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT weiqiujing disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT caoshuangyan disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT liaozetao disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT linzhiming disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT panyunfeng disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT huangjianlin disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT litianwang disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT jinou disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT wuyuqiong disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets
AT gujieruo disordersofmicrornasinperipheralbloodmononuclearcellsasnovelbiomarkersofankylosingspondylitisandprovocativetherapeutictargets